Last reviewed · How we verify
NCT06741930: Ketamin stdy
Pro-Epileptic Effects of IV Ketamine
Phase 4 trial testing Ketamine in Epilepsy in 300 participants. Completed in 30 August 2025.
30 August 2025
Quick facts
| Lead sponsor | Haseki Training and Research Hospital |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | screening |
| Enrollment | 300 |
| Start date | 1 December 2024 |
| Primary completion | 30 August 2025 |
| Estimated completion | 30 August 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Ketamine (ketamine) — full drug profile →
- Midazolam (midazolam) — full drug profile →
- Propofol (Propofol) — full drug profile →
Conditions studied
Sponsor
Haseki Training and Research Hospital
Who can join
18 and older, any sex, with Epilepsy or Seizure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators evaluated the safety and potential pro-epileptic effects of intravenous (IV) ketamine during procedural sedation in comparison with IV midazolam and IV propofol. Specifically, the study hypothesizes that IV ketamine, at doses used for procedural sedation, exhibits pro-convulsive properties, lowers the epileptic seizure threshold, and may induce interictal epileptiform discharges and/or seizures. Additionally, the investigators assessed the effects of these sedative agents on electroencephalographic (EEG) activity during procedural sedation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06741930
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ketamine
Trials testing the same drug.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT06963294 — Ketamine and Dexmedetomidine for Delirium in Joint Arthroplasty · NA · not yet recruiting
- NCT07294092 — Ketamine and Propofol NeuroImaging · EARLY_PHASE1 · recruiting
- NCT07197684 — Ultrasound Guided Pecs Block and Ketamine Infusion for Preventing Chronic Pain in Patients Undergoing Breast Cancer Surg · NA · not yet recruiting
- NCT06231563 — Ketamine for Veterans With Parkinson's Disease · Phase 2 · recruiting
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Haseki Training and Research Hospital trials
Trials by the same sponsor.
- NCT07502482 — The Effect of Magnesium on Post-spinal Headaches · not yet recruiting
- NCT07201181 — Maternal Smoking Exposure and Newborn Outcomes: Study Using Urinary Cotinine · not yet recruiting
- NCT07203716 — Preparing Kids for MRI Using VR · NA · not yet recruiting
- NCT07165743 — Evaluation of Fetal Bladder Emptying During the 11-14 Weeks' Ultrasound Examination as a Negative Predictive Marker for · active not recruiting
- NCT07179861 — Comparing Artificial Intelligence and Physicians: A Vignette-Based Study in Pediatric Clinical Decision-Making · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06741930 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Haseki Training and Research Hospital
- Last refreshed: 15 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06741930.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing